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Non-viral vectorAmorphous mesoporous silica nanoparticles (‘protocells’) that support surface lipid bilayers recently character-
ized in vitro as carrier constructs for small drug and DNA delivery are reported here as highly biocompatible both
in vitro and in vivo, involving the brain and spinal cord following spinal delivery into the lumbosacral subarach-
noid space (intrathecal; i.t.). Speciﬁcally, positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-Propane
(DOTAP)–cholesterol (DOTAP:Chol) liposome-formulated protocells revealed stable in vitro cargo release kinet-
ics and cellular interleukin-10 (IL-10) transgene transfection. Recent approaches using synthetic non-viral vector
platforms to deliver the pain-suppressive therapeutic transgene, IL-10, to the spinal subarachnoid space have
yielded promising results in animal models of peripheral neuropathy, a condition involving aberrant neuronal
communication within sensory pathways in the nervous system.
Non-viral drug and gene delivery protocell platforms offer potential ﬂexibility because cargo release-rates
can be pH-dependent. We report here that i.t. delivery of protocells, with modiﬁed chemistry supporting a
surface coating of DOTAP:Chol liposomes and containing the IL-10 transgene, results in functional suppres-
sion of pain-related behavior in rats for extended periods. This study is the ﬁrst demonstration that protocell
vectors offer amenable and enduring in vivo biological characteristics that can be applied to spinal gene
delivery.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The development of synthetic non-viral vectors for gene therapeu-
tic purposes has steadily increased during the past 10 years, an effort
that is reﬂected by increased non-viral gene therapeutic clinical trials
worldwide [1,2]. While viral vectors are superior in gene transfection
efﬁciency, non-viral gene transfer systems are associated with less
safety concerns. The application of central nervous system (CNS)
non-viral gene transfer to express therapeutic proteins is signiﬁcantly
underexplored in light of the broad-ranging therapeutic potential in
controlling a host of neurological diseases. The arsenal of potential
clinical gene delivery platforms includes cationic lipids and peptides,+1 505 272 8082.
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-ND license.co-polymers, polymeric micelles, and modiﬁed silica nanoparticles
[3–5]. Indeed, a signiﬁcant amount of progress toward our under-
standing and utilizing mesoporous silica nanoparticles (MSN) for
controlled drug and gene release, while optimizing biocompatibility,
has occurred in recent years [6]. Silicas are present in crystalline
and non-crystalline (amorphous) forms, with amorphous silica oc-
curring either naturally or are synthesized. While crystalline silica is
widely associated with adverse health effects including silicosis that
involves proinﬂammatory cytokine-mediated pathogenesis, virtually
no toxicity has been identiﬁed with synthetic amorphous silicas at
moderate doses [7,8]. Therefore, synthetic amorphous silicas have
been explored in biomedical applications including targeted drug de-
livery for cancer chemotherapeutics and DNA delivery for gene ther-
apy [9,10]. The major advantage of using synthesized MSNs is that
their surface can be chemically modiﬁed resulting in improvements
in their drug cargo capacity as well as facilitation of tunable release
rates which further enhances their biocompatibility and functional
capabilities [11].
Mesoporous silicas contain a porous structure with hundreds of
channels referred to as mesopores, which are able to adsorb bioactive
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(>900 m2/g), large pore volumes (>0.9 cm3/g), a tunable pore size
(~1–30 nm), and good chemical and thermal stability; all of which
contribute to their suitability for controlled drug release applications.
Additionally important, efﬁcient cellular uptake of mesoporous silica
particles is size-dependent, with optimal uptake occurring at the
sub-micron scale with potential for controlled DNA release [5].
Non-viral spinal gene therapy to suppress neuropathic pain is a
relatively new approach that has resulted in successful therapeutic
outcomes in a variety of animal models of pathological pain produced
by peripheral nerve inﬂammation and/or trauma from systemic can-
cer chemotherapeutic administration, peri-sciatic immune activators,
or chronic constriction injury [12–16]. However, high transgene doses
and limited cargo loading efﬁciency of polymer platforms were
observed, which may minimize the clinical utility of this delivery
method. One approach to circumvent these limitations is to deliver
therapeutic genes utilizing MSNs for transgene delivery due to their
ﬂexibility in cargo loading and release.
In the present work, in vitro and in vivo long-duration biocompat-
ibility, biodistribution, and functional gene expression following
delivery to the spinal cord was conducted using cationic amine-
chemically-modiﬁed (functionalized) mesoporous silica cores with
~2 nm diameter pores prepared by aerosol-assisted self-assembly,
with phospholipid bilayers fused to the core surface. The term
‘protocell’ will be used to reference MSN-supported lipid bilayers
to maintain consistency of nomenclature with the initial published
description of their manufacture and characterization [9,17,18].
The principle attractiveness of utilizing these protocells as drug and
gene delivery platforms is in their potential for increased drug con-
tainment properties, and the tenability of surface chemistry modiﬁ-
cations tailored to speciﬁc cargos.
2. Materials and methods
2.1. Animals
A total of 62 adult, male Sprague–Dawley rats (Harlan Labs, Houston,
TX); 300 ± 5 g were double housed at 21 ± 4 °C in light controlled
rooms (12:12 light:dark) and fed standard rodent chowandwater avail-
able ad libitum. All procedures were approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of the University of New
Mexico, and conducted in accordance to the guidelines recommended
by the International Association for the Study of Pain for the handling
and use of laboratory animals.
2.2. Behavioral assessment for sensory changes
Baseline spinal cord activity is evaluated using the well-
characterized protocol for assessing threshold responses to light
touch applied to the hindpaws with a series of calibrated monoﬁla-
ments (0.4–15 g). The monoﬁlaments generate a touch stimulus
when applied to the hindpaw that induces a paw withdrawal re-
sponse within 8 s [19,20]. Paw withdrawal sensory thresholds are
highly sensitive to subtle inﬂammatory perturbations in the spinal
cord, as normal hindpaw response thresholds (5–10 g) are present
during healthy, non-pathological conditions [20,21] while response
thresholds dramatically decrease (b1 g) in the presence of inﬂamma-
tory signaling [20,21]. This behavioral response phenotype is used as
an indicator of spinal cord health. Prior to behavioral thresholds, rats
were habituated to the testing conditions for 4 consecutive days,
1 h/day, in a quiet dimly lit and temperature controlled room
(26.0–27.0 °C), where rats were placed on top of an open grid of
bars with 2 mm thickness, spaced 8 mm apart to allow access to
the entire plantar surface of the hindpaw for tactile stimulation. Re-
sponse thresholds were determined by a logarithmic series of calibrated
Semmes-Weinstein monoﬁlaments (von Frey hairs; Stoeling, WoodDale, IL). Testing of behavioral thresholds were conducted identically to
that described previously [20,21]. Brieﬂy, baseline (BL) responses to
light mechanical touch stimuli were assessed using 10 monoﬁlaments,
eachwith a log-stiffness value, deﬁned as log10 (milligrams×10), values
in grams follow in parentheses: 3.61 (.407), 3.84 (.692), 4.08 (1.202),
4.17 (1.48), 4.31 (2.04), 4.56 (3.63), 4.74 (5.49), 4.93 (8.51), 5.07
(11.75) and 5.18 (15.14). BL values derived from three threshold assess-
ments, at 20 min intervals,were averaged for the right and left hindpaws
separately. After injection of protocells, threshold responses were
re-assessed at .5, 1, 2, 3, 24 and 72 h. In those rats that underwent unilat-
eral sciatic nerve injury, thresholds were reassessed at 3 and 10 days
post-surgery and every 2 days, up to 32 days post-peri-spinal (intrathe-
cal; i.t.) protocell injection. To assess normal food consumption as an in-
dication of general health, bodyweightsweremeasured following2, 4, 8,
12, 14, 21, 28, and 56 days following i.t. administration of protocells.
2.3. Chronic constriction injury (CCI)
The surgical procedure for chronic constriction injury (CCI) was
performed identically as previously described [22]. Brieﬂy, under
isoﬂuorane anesthesia (1.5–2.0 vol.% in oxygen), the mid to lower
back and dorsal thigh were shaved and cleaned with diluted Bacti-Stat
AE (EcoLab HealthCare Division, Mississauga, Ontario, Canada). Using
aseptic procedures, the sciatic nerve was carefully isolated and four
chromic gut sutures (Ethicon, Somerville, NJ) were loosely tied around
one sciatic nerve. The overlying muscle was sutured closed with two,
sterile, silk sutures (Ethicon, Somerville, NJ), and the overlying skin
was closed with wound clips. The sciatic nerve of sham-operated rats
were identically exposed but not ligated. Animal body weight was
recorded and recovery from anesthesia was observed within 10 min.
2.4. Intrathecal (i.t.) injections
Injectionswere acutely administered and conducted as described pre-
viously [14,23]. Brieﬂy, ratswere anesthetizedwith isoﬂuorane (5.0 vol.%
in oxygen) and an18-gauge cannula constructed froman18-gauge sterile
hypodermic needle (Becton Dickinson & Co., Franklin Lakes, NJ) removed
from its hub was inserted percutaneously between lumbar vertebrae 5
and 6 (L5–6). During this time, a small amount of cerebral spinal ﬂuid
(CSF) efﬂux from the 18-gauge cannula and a tail ﬂick were observed, in-
dicating subarachnoid catheter placement. A 1 ml Hamilton syringe
connected to a 30-gauge, 0.5 inch needle inserted into a catheter com-
posed of a 30 cm-length polyethylene tubing (PE-10; cat# 427401;
Becton Dickinson, Sparks, MD) was then used to draw up DOTAP:Chol
or DOPC protocells (1.0, 0.1 or 0.01 mg) in a total volume of 20 μl sterile,
isotonic saline. The drug-ﬁlled PE-10 catheter was then inserted into the
open end of the 18-gauge guide cannula and advanced 7.7 mm rostrally,
placing the internal portion of the PE-10 catheter at the lumbosacral en-
largement of the spinal cord where axon terminals of sciatic afferent
nerve ﬁbers synapse onto pain-relevant spinal cord neurons. Injections
were given over a 0.5–1 minute interval. Following drug injection, the
PE-10 catheterwas removed followedby removal of the 18-gauge cannu-
la, and both were discarded. The total time required for these i.t. injec-
tions was 2–3 min. All animals displayed full motor activity following
recovery from anesthesia.
2.5. Preparation of plasmid DNA
The plasmid vector used in these studies was identical to that pre-
viously described [23]. This plasmid's transcriptional cassette consists
of a cytomegalovirus (CMV) enhancer/chicken beta-actin (CB) pro-
moter driving the expression of rat IL-10 gene containing a point mu-
tation (F129S) and the SV40 polyadenylation signal. The identical
plasmid lacking the IL-10 gene was used as a control (control DNA).
Both plasmids were ampliﬁed in SURE II competent Escherichia coli
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Giga plasmid puriﬁcation kit (Qiagen, Valencia, CA).
2.6. Preparation of mesoporous cationic silica “core” protocells
The mesoporous silica particles were prepared by the surfactant
self-assembly method described previously [18,24]. Brieﬂy, a homoge-
neous solution of the soluble silica precursor, tetraethylorthosilicate
(TEOS; Sigma-Aldrich Corp., St. Louis, MO), and hydrochloric acid was
mixed in ethanol andwater. A surfactant, cetyltrimethylammoniumbro-
mide (CTAB; Sigma-Aldrich Corp., St. Louis, MO), with an initial concen-
tration much less than the critical micelle concentration was added
to lower the surface tension of the liquid mixture and act as the
mesoporous structure-directing template. Aerosol solutions of soluble
silica plus surfactant were then generated with nitrogen as a carrier
atomizing gas using a commercially available atomizer (Model 9392A,
TSI, Inc., St. Paul, MN). The aerosol droplets were solidiﬁed in a tube fur-
nace at 400 °C until dry. Once dried, a durapore membrane ﬁlter, kept at
80 °C, was used to collect the particles. As a ﬁnal step, the surfactant was
removed at 400 °C for 5 h via calcination. The surface of themesoporous
silica core in these studies was chemically modiﬁed with 10 wt.% or
15 wt.% by aminopropyltriethoxysilane (APTES; Sigma-Aldrich Corp.,
St. Louis, MO) conducted identically as previously described [17] to cre-
ate a positive surface charge to increase loading efﬁciency of negatively
charged cargo. Further, Liu and colleagues report the colloidal stability
of these protocells with lipid bilayers, excess amount of liposomes
(50 μg liposomes per 0.5 mg silica were used [18]).
2.7. Preparation of liposome-supported bilayers (protocells)
The lipids used in this study were either positively charged, 1,
2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP; cat. # 890890C;
Avanti Polar Lipids Inc., Alabaster, AL) or zwitterionic and neutrally
charged, 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; cat. #
850375; Avanti Polar Lipids Inc., Alabaster, AL). Cholesterol
(Sigma-Aldrich) was added to DOTAP in a 1:1 ratio (25 mg each),
as it has been reported to improve transfection efﬁciency when in-
cluded in cationic liposomes [25]. DOTAP:Chol was dissolved in chlo-
roform, followed by evaporation under nitrogen ﬂow. Phospholipids
were dissolved in chloroform at concentrations of 10–25 mg/ml. Lipid
aliquots of 2.5 mg were placed in scintillation vials. In some experi-
ments where lipids were examined under confocal microscopy, Alexa
Fluor 647, a red ﬂuorescent dye (absorption 650 nm and emission
658 nm; Invitrogen, Carlsbad, CA), was added at 2% for these labeling
and biodistribution studies. Chloroform was then evaporated under ni-
trogen ﬂow. The vials were then stored overnight in a vacuum oven to
remove remaining chloroform. Samples were stored at −20 °C until
used.
To prepare liposomes, vials were brought to room temperature
and samples were rehydrated with 1 ml buffer (10 mM MOPS,
pH 7.0, 60 mM NaCl) and shaken for 1 h, which resulted in a cloudy
suspension. The suspension was extruded through a 100 nm pore di-
ameter membrane with in a mini-extruder (Avanti Polar Lipids), and
repeated for a minimum of 21 times. The resulting liquid was placed
in a fresh vial and stored at 4 °C until used in the preparation of DNA
loaded protocells.
2.8. Preparation of DNA (either 18-bp or pDNA) loaded “protocells”
An 18 bp-DNA oligomer (5′-CTTGAGAAAGGGCTGCCA-3′) tagged
with 6-carboxylﬂuorocein (FAM, emission 520 nm, or ﬂuorescein iso-
thiocyanate, FITC emission 488 nm; Invitrogen, Carlsbad, CA) was used
to identify the safety proﬁle and anatomical location of protocell cargo
following i.t. injection. To load the silica core with pDNA in vivo behav-
ioral experiments, 35 μl of 200 μMDNAwas added to 3.5 mg of cationic
silica nanoparticles, gently mixed in sterile 0.5× PBS (25 mg/ml; 140 μlper 3.5 mg particles) and allowed to incubate for 5 min. In a sterile
microcentrifuge tube, 300 μl of 2.5 mg/ml of liposome mixture was
added and mixed with the nanoparticle/DNA mixture by pipetting
until homogeneous. The resulting mixture was allowed to sit at room
temperature for 1 h with occasional agitation by pipetting and then
centrifuged for 2 min. at 6000 RPM to remove excess lipids. The super-
natant was discarded, and the pellet was washed in sterile PBS followed
by centrifugation at 6000 RPM. Pellets (protocell/18mer-DNA-FAM/
lipid mixture) were washed 3× and resuspended in sterile PBS at 50, 5
or 0.5 mg/ml. For pDNA loading onto protocells in cell culture experi-
ments, identical steps were followed with DOTAP:Chol lipids
resuspendedwith PBS (pH 7.4) containing 5 μg rat pDNA-IL-10. Follow-
ing resuspension with PBS (pH 7.4), liposome size and zeta potential
were characterized by dynamic light scattering using a Zetatrac
Ultra151 dynamic light scattering (DLS) instrument (Microtrac Inc.,
Montgomeryville, PA) and Microtrac FLEX 10.6.1 analysis software.
Measurements were made in triplicate using a standard ﬁlter with
high resolution, high sensitivity and a scan time of 240 s. For in vivo
behavioral assessment of protocell-delivered IL-10 gene therapy, identi-
cal steps described above were followed with DOTAP:Chol lipids
resuspended in 50 mg/ml to yield a ﬁnal dose and concentration of
10 μg pDNA/mg protocell/20 μl PBS.2.9. Characterization of mesoporous silica particles
Transmission electron microscopy (TEM) images were acquired
with a JEOL 2010 200 kV high-resolution transmission electron mi-
croscope. The pore diameter was calculated by the Barret–Joyner–
Halenda (BJH) method [26]. Particle size distribution of 15 mol%
APTES modiﬁed mesoporous silica cores as measured by dynamic
light scattering. The nitrogen sorption isotherm of the silica particles
exhibit a Type IV nitrogen adsorption–desorption isotherms, as pre-
viously characterized [27]. Using the Barrett–Joyner–Halenda (BJH)
model, the pore diameter was determined revealing a narrow distri-
bution. The total surface area was calculated by the Brunauer,
Emmett & Teller (BET) method [28].2.10. Characterization of cargo release-rate from protocells
Mesoporous silica nanoparticles (25 mg) modiﬁed with 15%
APTES and supporting either a surface coating of DOTAP:Chol 1:1
(DOTAP:Chol) or DOPC lipid bilayer, were dispersed in 1 ml PBS to
give a concentration of 25 mg/ml 12.5 μl of 20 mM dextran–
tetramethylrhodamine (DexRho; 10,000 MW, Anionic, Molecular
Probes, Invitrogen, Carlsbad, CA, cat# D-1868) to yield ~250 μM.
The solution was agitated at room temperature for 45 min, and
50 μl aliquots of each protocell formulation for each timepoint
were centrifuged for 2 min, washed 3× with 200 μl of 0.25× PBS to
remove unincorporated dye and excess lipids. A total of 200 μl of
pH appropriate buffer was added to each sample (N = 3) to give a
ﬁnal concentration of 6.25 μg/μl. The particles and buffers were
kept at 37 °C. At designated timepoints, 1, 3, 6, 24, 48, 72, 96 and
168 h (1 week), samples were removed, centrifuged at 14,000 RPM
for 2 min to precipitate the silica. A 100 μl sample of supernatant
was then transferred into a borosilicate microcuvette to measure ab-
sorbance at 555 nm on a Beckman DU 530 UV/vis spectrophotometer
(Beckman-Coulter, Inc., Fullerton, CA). In order to determine the quan-
tity of dye released, absorbance readings from the supernatant samples
were compared against a set of standards from a serial dilution curve
based on known concentrations of dextran–tetramethylrhodamine.
The following buffers were brought to a 1 l volume in dH20 to generate
the corresponding pH values: 0.1 M acetic acid (pH 2), 0.1 M citrate
with 0.03% H2O2 (pH 4), 10.0 mM PBS (pH 7.4), 10.0 mM PBS with
0.1% BSA (pH 8.0), and 0.1 M Amino-Methyl-Propanediol (pH 10).
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For tissue collection, rats were euthanized by overdosing with sodi-
um pentobarbital (Abbott Laboratories, North Chicago, IL) at 72 h, and
2, 4 and 8 weeks (N = 3 rats for each timepoint and each protocell
formulation; DOTAP:Chol or DOPC). Blood samples were taken and
mixed with 0.1 ml heparin (APP Pharmaceuticals, LLC, Schaumburg,
IL) to prevent clotting. Transcardial PBS (warmed to ~45 °C; 3–5 min)
perfusion was followed by room temperature .01 M PBS; (3–5 min),
and then ice cold 4% paraformaldehyde (pH 7.24; 6–8 min) perfusion.
Spinal cord, brain, cervical nodes, thymus, spleen, kidney and liver
were harvested and post-ﬁxed in 4% paraformaldehyde overnight and
transferred to PBS and stored at 4 °C. Bone encased spinal cords
were placed in 10% ethylenediaminetetraacetic acid (EDTA) solution
(~3–4 weeks) to chelate calcium and soften bone for sectioning spi-
nal cord encased in the spinal column to maintain anatomical integ-
rity of the perispinal meninges. The entire spinal cord was cut and
cross-sectioned into ﬁve, 5 mm, segments starting at the i.t. injec-
tion site (pt 0) and proceeding both rostrally and caudally. Brain
and organ tissues were cryoprotected in 30% sucrose in (0.1 M
PBS + 50 μl 10% sodiumazide) for 24 h, embedded inO.C.T. compound
in cryomolds (cat# 4565-Sakura Finetek, Torrance, CA), ﬂash frozen in
45 °C isopentane on dry ice and ﬁnally stored at −80 °C until the
time of sectioning. For cryosectioning, 10 μm tissue slices were cut on
a cryotome, Microm HM 505E (Zeiss, Thornwood, NY), and placed on
Vectabond (Vector Laboratories, Burlingame, CA) coated slides.
2.12. Quantitative spectral imaging
For FAM-tagged DNA, multi-spectral tissue imaging and quantiﬁ-
cation were conducted as previously described [29]. Brieﬂy, images
were obtained using an Axioscope microscope connected to a Nuance
Camera 2.8 (FX) Multispectral Imaging System (Cambridge Research
and Instrumentation Inc., (CRI) Woburn, MA) [29]. This camera con-
tains a liquid crystal tunable ﬁlter (LCTF) capable of ﬁltering light
from 400 to 720 nm, and can capture a series of images of a particular
tissue region at 10 nm wavelength increments. Every pixel of every
image (series collected at speciﬁc 10 nm wavelength increment)
was then analyzed by CRI software to determine its peak spectral in-
tensities from 400 to 720 nm. For each tissue type examined, the soft-
ware subtracts background autoﬂuorescence, deﬁned as any spectral
emission falling outside the 10 nm wavelength range used for analy-
sis. True FAM signal (excitation 494 nm, emission 522 nm) was
determined from a control cover-slipped slide on which a small
drop of 100× diluted FAM-tagged DNA 18-oligomer was placed. The
autoﬂuorescence was determined by imaging naïve tissue. The inten-
sity of FAM ﬂuorescence across the full wavelength range (400–720)
was calculated using theNuance computer software. Aminimum thresh-
old intensity was set automatically by the software and FAM spectral
emissions below this point were not included in the calculation. The
FAM intensity signal “counts” were then averaged per exposure time
(sec) per mm2 area for each image collected (signal counts/s/mm2).
An image was acquired for each of 4 slices (n = 4) per tissue region
(e.g. spinal cord) per rat, and then averaged to generate a mean value
for a tissue region per rat (N = 3 rats/treatment group). An overall
mean value is calculated for each treatment group, and the data are
reported as signal counts/s/mm2. Detailed information regarding the
computer software can be found on the Caliper Life Science website, a
subsidiary of Perkin-Elmer (URL: http://www.caliperls.com/products/
microscopy-imaging-analysis/microscopy-imaging/nuance-fx.htm).
2.13. Immunohistochemistry
Tissues were collected and sliced identically as described above
(n = 3 rats with 12 slices per anatomical area). Tissues were perme-
abilized with 0.5%Triton-X and blocked against non-speciﬁc antibodybinding in PBS + 5% BSA + 0.5% Triton-X for 1 h at RT. Primary anti-
bodies were diluted in a solution of PBS with 0.1% BSA, 0.3% Triton-X
with 0.1% sodium azide and incubated overnight at RT in a humidity
chamber with slight rotation. Primary antibodies were diluted as
follows: ED1/CD68 (1:300; a marker for macrophage activity, ED1-cat#
SC-7084, Santa Cruz Biotechnology, Santa Cruz, CA); GFAP (1:300,
astroglia; cat# AB5804, Millipore, Temecula, CA), Cd11b (microglia/
macrophage, 1:300, monoclonal OX42, cat# MCA 275EL, AbD Serotec,
Raleigh, NC), and Cleaved-Caspase 3 (Asp175) (apoptotic cells, 1:200,
cat#9664 Cell Signaling Technology, Beverly, MA). Slices were
washed 3× with 0.1 M PBS and then incubated for 2 h at room tem-
perature in a dimly lit room at a 1:200 dilution of a Rhodamine
Red-labeled secondary antibody (Jackson Immunoresearch Laborato-
ries, West Grove, PA) in the same solution as that used for primary
antibodies. Unbound secondary antibody was removed by 3× washes
(5 min each in 0.1 M PBS). Slices were then covered with the
ﬂuoro-protectant, Vectashield, containing the nuclear stain DAPI (4,
6-diamidino-2-phenylindole) (Vector Laboratories, Burlingame, CA),
cover slipped, and stored at 4 °C. Three slides, with 3 tissue sections
on each slide (n = 9), were examined for each primary antibody.
As a negative control, no primary antibody was added to an additional
slide. A positive control for the Caspase-3 antibody was also included
in this experiment. Cultures of Raw 264.7 mouse macrophage cells, a
cell type similar to that present in CNS meninges, were treated with
bacterial lipopolysaccharide (LPS; 1 μg/ml) for 2 h to initiate apopto-
sis, and then were subjected to the activated Caspase-3 antibody. Red
apoptotic cells stained positively and conﬁrmed the integrity of the
Caspase-3 antibody (data not shown). Tissues or cells were examined
using an Olympus BX-60 ﬂuorescent microscope, Olympus D71 camera
and software (Olympus America, Inc., Center Valley, PA).
2.14. Confocal imaging
To determine subcellular location of FAM-tagged 18 bp DNA load-
ed onto protocells, or FITC-tagged 18 bp DNA loaded onto liposome-
tagged Alexa Fluor 647, 40× or 20× confocal image z-stacks were
obtained with a Zeiss Axiovert 100 inverted microscope (Carl Zeiss
Laser Optics, Oberkochen, Germany) using LSM510 Image Acquisition
software. The microscope excited the ﬂuorophore of interest DAPI,
FAM, FITC, Rhodamine, or Alexa Fluor 647 with one of three lasers:
argon—405 nm; NeHe1—543 nm; and HeNe2—633 nm respectively.
2.15. Cellular transfection
For human embryonic kidney cell (HEK 293) cultures, cells were
purchased from American Type Culture Collection (ATCC; Manassas,
VA-cat# CRL-1573), and maintained in Minimum Essential Medium
containing Earle's Salts and l-glutamine (Invitrogen, cat# 11095) to
which was added 10% heat inactivated fetal calf serum (FCS) (Gibco,
cat#10438) and 100 U/ml penicillin and 100 μg/ml Streptomycin
(Gibco, cat# 15400). Cells were allowed to grow to 80% conﬂuence
and were then trypsinized with 0.05% Trypsin-EDTA (Gibco-cat#
15400) to loosen cells. The cell suspension was centrifuged in a sterile
50 ml conical tube at 1500 RPM for 5 min at 4 °C. After adding 20 ml
of fresh media, the cells were counted by standard technique on a he-
mocytometer and passed to a new sterile T-75 ﬂask, plated at
10.0–15 × 106 at each pass. Cells were incubated at 37 °C with an at-
mosphere of air, 95% and CO2, 5% until experimental procedures.
For transfection with protocells, HEK 293 cells were plated at
1.0 × 106 cells/ml on 24 well sterile poly-D lysine coated culture
plates (Becton Dickinson, Twin Oak Park, Bedford, MA) in 1 ml sterile
MEM or DMEM respectively, both supplemented with 10% heat
inactivated FCS and 100 U/ml penicillin and 100 μg/ml streptomycin
and allowed to grow 24 h to 80% conﬂuence. Media was exchanged
with 1 ml fresh media containing 500, 50, 25, 10, and .5 μg/ml DOTAP
or DOPC protocells loaded with pDNA-IL-10-GFP (5, 0.5, 0.25, 0.1 or
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experiment, media was exchanged with 1 ml fresh media containing
LPS (10 ng), naked pDNA-IL-10 (5 μg), or DOTAP:Chol + pDNA-IL-10
(5 μg) lacking the mesoporous silica core. The protocell containing
media was removed after 5 h and replaced with fresh media. Media
was collected 24 h later and analyzed for GFP transfection (green ﬂuo-
rescence) and/or IL-10 protein release using rat IL-10 speciﬁc
Quantikine™ ELISA kit (R&D Systems, Minneapolis, MN) according to
manufacturer's instructions, or immunostainingwith IL-10 primary an-
tibody (R&D Systems, Minneapolis, MN) with Rhodamine 2° antibody
in a procedure identical to that used for the immunohistochemical
staining outlined above.
2.16. Cell viability assay
HEK 293 cells were plated at 5–6 × 106 cells/ml on 24-well sterile
poly-D lysine coated culture plates (Becton Dickinson, Twin Oak Park,
Bedford, MA) in 1 ml sterile MEM supplemented with 10% heat
inactivated FCS, 100 U/ml penicillin and 100 μg/ml streptomycin, and
allowed to grow to 80% conﬂuence. Media was removed and 1 ml of
fresh media was added containing 500, 50, 25, 10, and .5 μg/ml
DOTAP or DOPC protocells loaded with pDNA-IL-10-GFP, or blank
protocells. The media was removed after 5 h and replaced with fresh
media and the cells were allowed to incubate for an additional 21 h.
Cells were removed with a standard sterile cell scraper and 500 μl of
cell suspensions placed in a ﬂow cytometry tube on ice (Falcon cat#
352008—Becton Dickinson Labware, Franklin Lakes, NJ). Saponin
(0.1%) was used to induce cell death for assay to compare against
other experimental manipulations. 3 min before examination by ﬂow
cytometry (Facscan4, Becton Dickinson), 50 μl of 10 μM ethidium-
homodimer D-1 was added to label dead cells.
2.17. Mouse macrophage (Raw 264.7) cells for nitric oxide assay
Raw 264.7 cells were obtained from American Type Culture Collec-
tion (ATCC, Manassas VA, USA—cat# TIB-71) and cultured as adherent
cells in Dulbecco's Modiﬁed Eagle's Medium (Sigma-Aldrich, cat#
D6429) supplemented with 10% heat-inactivated fetal bovine serum
(Gibco, cat# 10082-147) and 100 U/ml penicillin and 100 μg/ml strep-
tomycin (Gibco—cat#-15140122) and maintained at 37 °C under hu-
midiﬁed 5% CO2 atmosphere. Cells were grown to 85% conﬂuency,
collected by scraping, and sub-cultured for 3 passages. For these exper-
iments, dead cells were counted by hemocytometer using trypan blue
exclusion.
2.17.1. Measurement of nitric oxide production
Raw264.7 cellswere seeded at a density of 2.75 × 105 cells/ml in 24
well plates 24 h prior to experimentation and maintained at 37 °C
under humidiﬁed 5% CO2 atmosphere. At 85% conﬂuency, the superna-
tant was exchanged with DMEM containing different formulations of
DMEMandprotocells or protocell constituents and followedby a 2 h in-
cubation then washed twice in PBS (pH 7.4, Gibco—cat# 10010). Wells
treated with 10 ng/ml lipopolysaccharides from E. coli (LPS, Sigma-
Aldrich, cat# L6529) were exposed to DMEM containing LPS for
10 min followed by removal and washed twice in PBS. Nitric oxide pro-
ductionwasmeasured using the commercially available Griess Reagent
System (Promega, USA, cat#-G2930) according to the manufacturer's
instructions. Absorbance was measured at 550 nm using a Tecan
Inﬁnite® plate reader (Tecan Systems, Inc., San Jose, CA). All experi-
ments were run in triplicate.
2.18. Data analysis
Psychometric behavioral analysis was performed as previously de-
scribed [20] to compute the absolute threshold that resulted in the
50% hindpaw withdrawal response. As described previously [20,21,30]withdrawal thresholds were determined by using the software pro-
gram, PsychoFit. The software for PsychoFit may be downloaded from
L.O. Harvey's website (http://psych.colorado.edu/~lharvey). This pro-
gram ﬁts the pattern of hindpaw responses for each timepoint to a
Gaussian integral psychometric function and generates a 50% threshold
value for that timepoint. As such, parametric statistical analyses
(repeated measures ANOVA) are applied to determine the statistical
signiﬁcance between treatment groups at multiple timepoints using
the computer software, GraphPad Prism, version 4.03 (GraphPad Soft-
ware Inc., San Diego, CA). All other statistical analyses were performed
using the computer software, GraphPad Prism, version 4.03 (GraphPad
Software Inc., SanDiego, CA). All data is expressed asmean ± SEM. Post
hoc analysis was completed using Bonferroni's test.
3. Results
Mesoporous silica particle cores were prepared by the surfactant
templated aerosol-assisted self-assembly method previously developed
and communicated [18]. The resulting hydrophilic nanoparticles were
further modiﬁed with APTES and characterized by a uniform, ordered
and connected mesoporosity (Fig. 1A), with a positive of 24 ± 5 mV in
0.5× PBS, or when fused with DOTAP:Chol or neutral DOPC, 4.5 mV ±
2.2 mV or −11.4 ± 3.6 mV, respectively. The average size is ~230 nm
with a speciﬁc surface area of 935 m2/g and pore diameter of 2–5 nm
(Fig. 1B, D). Cryogenic TEM image reveals the liposome bilayer that is
~4 nm thick (white arrows, Fig. 1C). Protocells formulated with DOPC
lipids resulted in a cargo loading of dextran tetramethylrhodamine
(DexRho) at a capacity of ~13.49 μg and protocells formulated with
DOTAP:Chol lipids exhibited a cargo loading capacity of ~16.12 μg
DexRho.
Protocells with either DOPC or DOTAP:Chol formulations were
characterized separately for their release of DexRho cargo, in which
separate aliquots were individually incubated in pH solutions ranging
from 2 to 10 for durations of 1 to 168 h (Table 1 and Fig. 1F, G). Both
DOPC and DOTAP:Chol formulated protocells revealed an increase in
cargo release at pH 7.4 compared to 6.0 that continued through 24
and 48 h, respectively (Fig. 1F, G). Both pH 6 and pH 7.4 simulate
pH environments present extracellularly or in endosomal compart-
ments. Additionally, a characterization of DOPC and DOTAP:Chol for-
mulated protocells loaded with DexRho cargo at a full range of pH
levels (Table 1) is provided to determine cargo stability under dispa-
rate conditions that can occur during unique manufacturing condi-
tions or under highly acidic conditions that are present during
cellular inﬂammatory processes.
3.1. In vitro cellular viability is substantial
Cells remain viable following application of protocells formulated
with DOTAP:Chol or DOPC. HEK cells were incubated with
10–500 μg/ml protocells formulated with DOTAP:Chol or DOPC
containing plasmid DNA encoding the anti-inﬂammatory cytokine,
interleukin-10, and the reporter gene, green ﬂuorescent protein
(pDNA-IL-10/GFP; 10 μg/mg protocells) for 24 h. Protocells without
cargo served as controls. To examine the effects of DOTAP:Chol or
DOPC protocells containing pDNA-IL-10/GFP cargo on cellular viabil-
ity, ﬂow cytometry was used by applying ethidium-homodimer-1
(EH-1) to stain the cells. EH-1 enters the cell nucleus and intercolates
with DNA only in dead or dying cells in which the membrane is
breaking down. Thus, EH-1 does not interact with DNA of live cells
with intact membranes. Excitation of EH-1 at 528 nm leads to
617 nm emission (red ﬂuorescence), which is detected by the ﬂow
cytometer, and each dead cell is counted. The percentage of dead
cells is quantiﬁed per 10,000 cells. The percent of live cells was deter-
mined (Fig. 2). Cells left untreated served as an index of basal cell
viability, which was observed to be >98%. To ensure dead cell quan-
tiﬁcation, a separate group of cells were treated with 0.1% saponin,
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Fig. 1. Characterizations of protocells. (A) TEM image of mesoporous silica nanoparticles; scale bar = 50 nm. (C) Inset: Cryogenic TEM image revealing the liposome bilayer that is
~4 nm thick (white arrows); scale bar = 50 nm. (B) Particle size distribution of 15 mol% APTES modiﬁed mesoporous silica cores as measured by dynamic light scattering. The
average particle diameter of the mesoporous silica cores is 230-nm with a rather wide particle size distribution reﬂecting that of the aerosol generator. The surface of the
mesoporous silica core in these studies was chemically modiﬁed with 15 mol% aminopropyltriethoxysilane (APTES) to impart a positive surface charge (24 ± 5 mV in 0.5×
PBS) that increases loading efﬁciency of negatively charged cargo. When fused with positively charged DOTAP/DOPC or neutrally charged DOPC-based liposomes, the surface charge
was measured in 0.5× PBS to be 4.5 mV ± 2.2 mV or−11.4 ± 3.6 mV, respectively. (D) Nitrogen sorption isotherm of 15% aminated silica nanoparticles is a type IV isotherm with
a narrow hysteresis loop, typical of a 2D hexagonal mesoporous silica. (E) The pore diameter was determined to be 2–5 nm with a narrow distribution using the Barrett–Joyner–
Halenda (BJH) model. The Brunauer–Emmett–Teller (BET) surface area is ~935m2/g, with a pore volume ~0.48 cm3/g and the porosity of 0.52. (F) DOPC protocells and (G) DOTAP:
Chol protocells examined from 1 to 168 h at pH 6 and 7.4 (N = 3 samples/pH values/timepoint). The negatively charged ﬂuorophore, dextran tetramethylrhodamine (DexRho)
loaded protocells served as anionic cargo. For DOPC protocells, cargo release time-dependently increased to 24 h and remained relatively stable (~45) thereafter through 168 h
(F(7,32) = 8.728; p b 0.0001), with initially greater cargo release at pH 7.4 than at pH 6.0 (F(1,32) = 51.0; p b 0.0001). DOTAP:Chol protocell cargo revealed a similar release pattern
to DOPC protocells with the exception that increased cargo from DOTAP:Chol continued to increase through 48 h (F(7,32) = 6.98; p b 0.0001) with release appearing consistent
thereafter. Also similar to DOPC, cargo release from DOTAP:Chol protocells is initially greater at pH 7.4 compared to pH 6.0 (F(1,32) = 15.42; p b 0.001). Thus these data suggest
that cargo retention is greatest at pH 6.0 in both DOPC and DOTAP:Chol formulated protocells. Note: while standard error of the mean (SEM) is provided indicating sample variance,
% conﬁdence interval (%CV) is additionally provided along the X-axis. The pattern of greater cargo release that is somewhat pH sensitive for the ﬁrst several days suggests that time
and pH may be important factors that inﬂuence initial drug-delivery kinetics.
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DOTAP:Chol or DOPC resulted in b5% dose-related decrease in cell vi-
ability compared to live controls and remained stable even at the
highest dose of 500 μg/ml. Thus, cells exposed to DOTAP:Chol or
DOPC protocells remained healthy, suggesting that DOTAP:Chol or
DOPC protocells lack overt toxicity in vivo.3.2. Spinal delivery of protocells is well tolerated in an animal model
Light touch sensory threshold assessment is highly sensitive to
subtle perturbations in spinal cord homeostasis. Increases in local spi-
nal immune signaling molecules lead to spinal sensitization of pain-
related projection neurons resulting in a hypersensitivity to light
Table 1
Characterization of anionic DexRho-loaded DOPC and DOTAP:Chol protocells at various pH values over time. To fully characterize the stability of cargo release at extreme pH values
as well as at physiologically relevant pH values, DexRho cargo release was examined at discrete timepoints at pH values ranging from 2 to 10. The samples (N = 3/conditions) were
averaged (mean) and the sample variance is presented (SEM) as well as the sample % coefﬁcient of variation (%CV) that provides comparisons between independent datasets that
are sensitive to small changes in the sample means. Compared to DOTAP:Chol formulated protocells, the cargo from DOPC formulated protocells at pH 2 is retained across time,
while similar to DOTAP:Chol, the greatest cargo release is observed at pH 10 that moderately increases with time. Thus, both protocell formulation (DOTAP:Chol and DOPC) and
pH signiﬁcantly inﬂuence cargo release over time (F(77,192) = 1.60; p b 0.01).
pH 2 pH 4 pH 8 pH 10
Lipid
formulation
DOTAP:Chol DOPC DOTAP:Chol DOPC DOTAP:Chol DOPC DOTAP:Chol DOPC
Hours Ave SEM/%CV Ave SEM/%CV Ave SEM/%CV Ave SEM/%CV Ave SEM/%CV Ave SEM/%CV Ave SEM/%CV Ave SEM/%CV
1 30.22 5.01/23.36 18.90 7.57/56.45 30.12 1.61/7.55 24.5.4 6.62/38.03 38.41 6.24/22.92 37.97 0.68/2.53 37.20 7.72/29.27 50.53 5.64/15.73
3 31.09 2.18/9.87 24.36 2.34/13.54 34.45 1.31/5.38 23.33 8.48/51.30 47.26 5.68/16.96 38.38 4.53/16.65 47.86 6.53/19.24 56.54 7.39/18.82
6 23.47 0.64/3.86 22.23 2.01/12.72 31.94 6.39/28.19 34.43 7.18/29.40 42.68 6.94/22.93 48.02 4.38/12.88 48.68 9.24/26.76 66.68 5.82/12.3
24 23.15 0.05/0.32 18.99 1.23/9.12 38.75 3.83/13.94 35.41 7.69/30.60 39.68 7.68/27.28 51.97 4.63/12.57 67.07 8.10/17.03 79.69 10.95/9.38
48 26.35 3.24/17.35 17.09 2.45/20.23 45.58 2.26/7.0 39.07 6.86/24.75 43.60 7.30/23.62 54.93 9.17/23.54 71.40 12.58/24.84 77.16 7.26/13.26
72 28.42 1.32/6.53 17.92 3.23/25.39 45.82 2.22/6.84 29.09 8.11/39.29 47.39 8.68/25.83 42.88 2.94/9.68 81.17 11.44/19.87 77.69 11.36/20.61
96 31.07 4.53/20.56 17.04 2.04/16.87 40.88 1.07/3.68 39.47 8.58/30.64 52.06 8.69/53.53 51.81 11.92/32.44 78.29 13.38/24.11 73.45 1.49/2.85
168 38.60 2.30/8.38 12.05 4.75/55.63 42.05 3.05/10.23 28.49 7.69/38.06 50.45 6.49/18.13 50.50 10.29/28.73 81.48 11.36/19.66 91.17 9.49/14.67
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central terminals also project to the affected spinal segment [19,20].
Thus, assessing alterations in light touch thresholds from basal values
following central nervous system protocell application can be a time-
ly, robust and reliable in vivo examination of protocell early-phase
toxicity within the local spinal cord compartment. Baseline (BL) sen-
sory threshold values for both hindpaws were recorded prior to an i.t.
injection of DOTAP:Chol or DOPC formulated protocells. Thresholds
close to 10 g of stimulus intensity were observed in all rats prior to
treatment (Fig. 3).
Following an i.t. injection of 0.01 or 1 mg DOTAP:Chol formulated
protocells, a small increase in light touch sensitivity of the left paw
was observed at 30 min and rapidly recovered to basal levels and
remained stable during a 72 hr observation period (Fig. 3A, B). Nor-
mal insigniﬁcant basal variations in paw thresholds were observed
in 0.01 mg protocell and control (Vehicle) injected rats. Conversely,
both 0.01 and 1 mg DOPC formulated protocells induced a small in-
crease in light touch sensitivity (values dropped to b1.0 g stimulus
intensity) in both the left and right hindpaws at 2 h, that mostly re-
covered to BL values during the remaining 72 h observation period
(Fig. 3C, D). The transient 2-hr increase in light touch sensitivity fol-
lowing DOPC formulated protocells was unexpected given reports
show that in vitro, DOPC toxicity is virtually absent. However,
in vivo subtle changes in the local spinal milieu may occur to a greaterFig. 2. Cells remain highly viable following application of DOTAP:Chol and DOPC
protocells containing pDNA-IL-10-GFP. Cells were incubated for 24 h with DOTAP:Chol
or DOPC protocells loaded with pDNA-IL-10-GFP or blank control protocells (no pDNA)
at varying concentrations across a 50-fold dose range, 500, 50, 25 and 10 μg/ml. Dead
cells were identiﬁed by ﬂow cytometry after staining with ethidium-homodimer-1.
Results are representative of the percentage of gated cells (average of 4 experiments)
compared to untreated control cells, **p b 0.01; and ***p b 0.0001.extent that alters early-phase toxicity and corresponding neuronal
processing of normal sensory stimuli. Nevertheless, normal body
weight gain was observed in all rats throughout an 8 week observa-
tion period during which time, animals remained active and
well-groomed (Fig. 3E). Taken together, these data support that i.t.
administration of DOTAP:Chol, lack alterations from normal sensory
processing and both DOTAP:Chol and DOPC formulated protocells
are well-tolerated in the peri-spinal region of rats.3.3. Intrathecal (i.t.) DNA delivered by DOTAP:Chol or DOPC protocells
remains closely associated with meninges
Non-coding 18 bp oligonucleotide DNA labeled with the
ﬂuorophore, FAM (Ex/Em 492/517 nm; green) delivered by either
DOTAP:Chol or DOPC formulated protocells remained closely associ-
ated with the cells of the meningeal layer in the spinal cord, but did
not penetrate tissue parenchyma. A representative spinal tissue sec-
tion near the i.t. injection site, revealed DOTAP:Chol protocells
containing FAM-tagged DNA (green) in/adjacent to the meningeal
layer (Fig. 4A–D), with cellular nuclei counter-stained with the nucle-
ar speciﬁc ﬂuorophore, DAPI. Glial cell astrocyte processes and
endfeet (astrocytes stained for glial ﬁbrillary acidic protein, GFAP;
red) are typically present at the neural-pial meningeal interface,
which are capable of taking up extracellular material. Yet, no
co-localization of FAM-tagged DNA protocell cargo within astrocytes
was observed (Fig. 4A, white arrow). However, immune-relevant
macrophage and microglia that normally reside in meninges and at
the neural-pial interface are highly efﬁcient phagocytic cells. Indeed,
FAM-tagged DNA containing protocells robustly co-localized with
macrophages/microglia (stained for CD11b antigen expression; red)
in the meningeal peri-spinal region. Co-localization appears yellow
(Fig. 4B, white arrow). While microglia are present (red) in the
deeper spinal parenchyma, FAM-tagged DNA is absent (Fig. 4B).
Caspase-3 is a well-characterized enzyme that plays a critical role in
the late stages of programmed cell death (apoptosis). Immunohisto-
chemical detection of Caspase-3 (red) was entirely absent in the spinal
cords and brains of rats where DOTAP:Chol formulated protocells were
present. A representative image of protocells containing FAM-tagged
DNA (green) in themeninges reveals no positive Caspase-3 immunore-
activity at 8 weeks following i.t. injection (Fig. 4C). Confocal examina-
tion of meningeal macrophage/microglial cells immunostained for
expression of ED1, a marker for active immune cells, revealed that
DOTAP:Chol protocells containing FAM-tagged DNA were closely asso-
ciated with the DAPI-stained peri-nuclear area of ED1 expressing cells
(Fig. 4D, white arrow).
**
*
#
# #
Fig. 3. In vivo characterization of the biocompatibility betweenDOTAP:Chol andDOPC protocells. For clarity, protocell type (DOTAP vs.DOPC) is separated and represented in graphs iden-
tiﬁed as DOTAP orDOPCdata, while the identical vehicle-treated group (assessed alongside the protocell-treatment groups during experimentation) is representedwith both the DOTAP-
and DOPC-treated animals. (A–D) Baseline (BL) threshold responses of both hindpaws (left and right) between all animal groupswere similar (F(9,20) = 0.288; p = 0.97). (A, B) Follow-
ing i.t. injection with either 1 or 0.01 mg of DOTAP:Chol or vehicle, left hindpaw threshold responses remained unchanged throughout the timecourse (0.5, 1, 2, 3, 24, 48 and 72 h)
(F(6,24) = 1.63; p = 0.181), however, right hindpaw thresholds were moderately reduced (F(6,24) = 3.45; p b 0.05). Post-hoc analysis revealed that thresholds responses 30 min
after DOTAP protocell injection were signiﬁcantly lower than vehicle treated animals (p b 0.05). (C, D) For DOPC-treated animals, while an overall decrease in thresholds was not ob-
served across the timecourse in left (F(24,60) = 1.88; p > 0.05) or right hindpaws (F(24,60) = 1.01; p > 0.05), a small and signiﬁcant decrease at 2 h in both hindpaws was observed
(p b 0.05). Throughout the 8-week observation, all animals exhibited normal grooming, activity, exploratory behavior and body weight gain following i.t. injection with DOTAP:Chol
or DOPC protocells. (E) At BL, there was no signiﬁcant difference in body weight between untreated (black triangles) and treated animals that received i.t. DOTAP:Chol (2 weeks, solid
gray circles; 4 weeks, solid gray diamonds; 8 weeks, solid gray squares) or DOPC protocells (2 weeks, solid black circles; 4 weeks, solid black diamonds; and 8 weeks, solid black squares)
(F(6,14) = 2.837, p > 0.05). Consistent and normal gain in body weight compared to their BL levels was observed prior to sacriﬁce at 2 weeks (F(10,30) = 3.02, p b 0.0001), at 4 week
(F(14,42) = 2.62, p b 0.0001), and at 8 weeks (F(16,48) = 3.65, p b 0.0001) during an 8-wk observation period occurred in control animals and those receiving protocells by i.t. injection
(n = 3 per group). *p b 0.05; and #p b 0.0001.
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in vivo with mesoporous silica liposome-supported bilayers, DOTAP:
Chol liposomes were labeled with Alexa ﬂuor-647 and adsorbed to
silica cores loaded with FITC-labeled 18-bp DNA. Rats were given a
single spinal i.t. injection of protocells (1 mg) and sacriﬁced 72 hlater to identify protocell lipid bilayers colocalized to the DNA cargo
under confocal microscopy. DNA cargo (green) is robustly observed
in the meninges surrounding the i.t. injection site (Fig. 4E), and
DOTAP:Chol supported liposomes (red) are identiﬁed in the peri-
spinal meninges (Fig. 4F). Light microscopy reveals the spinal tissue
EG
F
i.t.  Space meninges
Silica Core = red18-bp DNA = green
i.t. space
H
A B
C D
Fig. 4. Histological examination of DOTAP:Chol protocellswith 18-bp FAM-labeledDNA cargo in the spinal cord. Fluorescent histological examination of spinal cord sections near the lum-
bar spinal cord injection site (segments L3–4) 8 weeks after i.t. injection of DOTAP:Chol protocells loaded with DNA cargo (2 μg). (A) Protocells containing DNA cargo (green; white
arrow) are not colocalizedwith astroglia stained for glial ﬁbrillary acidic protein, GFAP (red) and do not penetrate the spinal parenchyma, but are localized to the spinal pia and arachnoid
matter. (B) Protocells localized to the peri-spinal meninges containing cells stainedwith themicroglia/macrophage antigen expression protein, Cd11b (red). Colocalization of Cd11bwith
DNA cargo (green) is observed as yellow (white arrow). (C) There is no evidence of cellular death in tissue in contactwith protocells, as indicated by the absence of positive staining for the
apoptotic marker, activated Caspase 3 (red) while protocell-containing DNA cargo (green; white arrow) is clearly present in the peri-spinal meninges. (D) Confocal image identifying
DOTAP:Chol protocell cargo of FAM-labeled DNA (green) in the peri-nuclear area (cell nuclei stained with DAPI; blue) of meningeal macrophage cells stained for the classic activation
marker, EDI (red;white arrow) in the dorsal spinal cordmeninges. Overlap reveals yellow cytoplasmic andperi-nuclear staining. All images are at 20×; scale bar = 40 μm. (E–F) Confocal
images identifying single-stranded FITC-labeled DNA cargo (2 μg) loaded onto DOTAP-formulated protocells with DOTAP labeled with Alexa-ﬂuo 647, which is visualized only under UV
light (red). (E) The confocal ﬂuorescent images reveal the presence of protocell cargo (green DNA) and (F) DOTAP:Chol liposome (Alexa-ﬂuo 647, far red) inmeninges at the site 3 days
following intrathecal injection. (G) The identical tissue region collected with light differential interference contrast (DIC) and (H) an overlay of both ﬂuorescent and DIC to verify
co-localization of silica-supported DOTAP:chol and its DNA cargo. Images are 10×; scale bar = 40 μm.
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image reveals clear colocalization of DNA cargo with liposomes (yel-
low) (Fig. 4H), suggesting that the protocell-cargo formulation is sta-
ble for 72 h in vivo.3.4. In vivo biodistribution of protocells
Eight weeks following i.t. injection, protocells remain in the CNS
and are not found in peripheral tissue. As the animals appeared to
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Fig. 5. The lipid bilayer formulation of the protocell determines the degree of spread throughout the CNS following an i.t. injection. Graphs are representative of the key data in the
corresponding Table 2. Fluorescent spectral signal from FAM-labeled 18-bp DNA cargo in cryostat-sliced tissue sections (n = 4) of DOTAP:Chol or DOPC protocell i.t. treated ani-
mals is compared to the spectra of background autoﬂuorescence from naïve animals. (A) In the brain at 72 h, no signiﬁcant signal from FAM-tagged DNA delivered by either DOTAP:
Chol or DOPC protocells was observed. However, by 8 weeks, compared to DOTAP:Chol protocell treated tissue and autoﬂuorescence, FAM-labeled DNA delivered by DOPC
protocells had signiﬁcantly increased (F(2,6) = 8.60; p = 0.0173). (B) In the lumbar spinal cord, DNA delivered by both DOPC and DOTAP:Chol protocells was present at both
72 h and 8 weeks (FAM signal analysis vs. autoﬂuorescence, F(2,6) = 6.18; p = 0.0348), with DNA levels at 72 h signiﬁcantly higher than those at 8 weeks (F(1,6) = 10.71;
p b 0.02).
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protocells, even at the highest dose, the biodistribution of protocells
within and outside of the central nervous system (CNS) was quanti-
ﬁed. In these experiments, rats received an i.t. injection of DOTAP:Table 2
Values (1 × E−04) of each anatomical region are an average of computer-generated spect
Yellow boxes indicate those areas in which the signal from FAM-labeled DNA cargo reach
Asterisks indicate the amount of signiﬁcance. At 72 h and 8 weeks, very low levels of DOPC
liver and kidney, while measurable amounts of DOTAP:Chol and DOPC were detected in th
Inside CNS
1 Brain
Cervical spine
10 mm rostral
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cord were examined to quantify protocells by spectral microscopy
analysis that allows computerized de-convolution and quantiﬁca-
tion of the true FAM-signal from background autoﬂuorescence
(Fig. 5 and Table 2).
The blood was negative for FAM detection (data not shown). The
highest amount of FAM levels at 72 h post-DOPTAP:Chol or DOPC
protocell injection was observed at the i.t. injection site in the lumbar
spinal cord, which signiﬁcantly decreased by 8 weeks (Fig. 5B). Only
DOPC formulated protocells containing FAM-tagged DNA accumulat-
ed in the brain by 8 weeks (Fig. 5A). Thus, differences in the
biodistribution between the two protocell lipid formulations were
observed. Also at 8 weeks, the DOTAP:Chol protocell FAM signal had
diminished and was only signiﬁcant locally, near the injection site,
suggesting that DOTAP:Chol formulated protocells may be optimal
to maintain localized drug effects, while leaving the brain and the
body primarily undisturbed.
Outside the central nervous system, FAM signal was negligible in-
cluding in the liver and kidney. At 72 h, a minor but signiﬁcant
amount of FAM was detected in the thymus following treatment of
both DOTAP:Chol and DOPC formulated protocells. The data repre-
sented in Fig. 5A and B are included in Table 1 to provide relative
comparisons in FAM detection levels with respect to FAM levels ob-
served in other tissue regions that in most cases, appear negligible.
These data additionally suggest that a large amount of protocellsDOTAP
Protocells
IL-10GFP
DOPC
Protocells
IL-10GFP
***
A
DOPC
Protocells
IL-10
Concentration protocells ug/mL 
Co
nc
en
tra
tio
n 
IL
-1
0 
pr
ot
ei
n 
pg
/m
L
DOTAP
Protocells
IL-10
**
B
Co
nc
en
tra
tio
n 
IL
-1
0 
pr
ot
ei
n 
pg
/m
L
Concentration protocells ug/mL 
Fig. 6. DOTAP:Chol protocells improve cellular transfection of pDNA-IL10 transgene. (A, C) In vit
containing the genes for both IL-10 andGFP by employing an internal ribosomal entry site, resul
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3.5. Protocell IL-10 gene delivery leads to robust transgene expression
Transfection of HEK cells with a bicistronic plasmid containing the
gene for IL-10 and GFP successfully resulted in the expression of IL-10
(Fig. 6A) aswell as GFP (Fig. 6C, inset), indicating functional IL-10 trans-
gene expression inGFP expressingHEK cells. Protocells formulatedwith
either DOTAP:Chol or DOPC and loadedwith plasmid DNA encoding the
IL-10 gene alone (pDNA-IL-10) or in combination with the reporter
gene, pDNA-IL-10/GFP, were incubated with HEK cells to examine
transgene IL-10 protein expression. It is important to note that HEK
cells do not produce IL-10 protein thus providing a reliable assay to
quantify transgene-speciﬁc IL-10 gene activation. Surprisingly, only
those protocells formulated with DOTAP:Chol containing pDNA-IL-10
or pDNA-IL-10/GFP resulted in a robust dose-dependent increase in
protein IL-10 levels compared to untreated controls, with the greatest
amount of protein (~900 pg/ml) produced following incubation with
500 μg/ml DOTAP:Chol formulated protocells. In contrast, IL-10 protein
from transgene IL-10 delivered by DOPC protocells containing either
pDNA-IL-10 or pDNA-IL-10-GFP was signiﬁcantly lower and reached
maximal values of no greater than 100 pg/ml. Additionally, naked
pDNA-IL-10 or DOTAP:Chol + pDNA-IL-10 resulted a dramaticallyD
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protocells improve the transfection efﬁciency of pDNA-IL-10 and that li-
posomes alone are signiﬁcantly less efﬁcient.
3.6. Protocells are functionally effective as gene delivery platforms
Given that IL-10 transgene delivered by DOTAP:Chol formulated
protocells yielded robust transgene-derived IL-10 protein levels in
cell culture (Fig. 6) and DOTAP:Chol protocells appeared to show
minimal toxicity in vivo (Fig. 3), we next asked whether DOTAP:
Chol formulated protocells containing pDNA-IL-10 could act thera-
peutically by delivering sufﬁcient amounts of the IL-10 transgene to
suppress light touch hypersensitivity (allodynia), a neuropathic con-
dition mediated by sensitization of spinal neurons that communicate
to brain areas about pain-related stimuli. Allodynia occurs when
non-painful stimuli are coded as painful. Following BL assessment of
withdrawal behavior to light touch tactile stimuli, rats underwent ei-
ther sham surgery or CCI of the sciatic nerve. Clear development of
allodynia was observed 3 and 10 days later (Fig. 7A, B). On Day 10,
rats received an i.t. injection of DOTAP:Chol formulated protocellscontaining pDNA-IL-10, pDNA-control (non-coding DNA), or
equivolume vehicle (20 μl). While sham rats remained stably non-
allodynic, a rapid and complete reversal from neuropathic allodynia
was observed in IL-10 treated rats. Neuropathic rats injected with
i.t. control pDNA or vehicle remained stably allodynic throughout a
26-day timecourse. It is important to note that a prior report demon-
strated an equivalent dose of i.t. naked pDNA-IL-10 lacks efﬁcacy to
reverse allodynia [12]. Taken together, these data show that
pDNA-IL-10 delivered to the peri-spinal regions by DOTAP:Chol
protocells was able to reverse allodynia to BL levels for almost
2 weeks. These data support that the production of IL-10 protein
from pDNA-IL-10 transgene loaded on protocells is functionally and
physiologically effective in reversing pain thresholds.
The toxicity proﬁle of protocells is minimal, as they do not lead to
subtle perturbations in cell stress, as assessed by the production of nitric
oxide (NO). In order to assess subtle and transient cell-stress responses
to the identical DOTAP:Chol protocell formulation examined for in vivo
spinal gene therapy, culturedmacrophage cells (Raw264.7)were exam-
ined, given the observed in vivo spinal co-localization of DOTAP:Chol
protocells with macrophages/microglial cells, as described above in
Fig. 4. Macrophages were assayed for NO following a 2-hour incubation
with whole protocells or the component silica core and lipid (DOTAP:
Chol) (Fig. 7C). Lipopolysaccharide (LPS) was included, as it is known
to produce robust enhancement of NO in this cell line [31–34]. As
expected, cells incubated with LPS for 10 min produced increased levels
of NO compared to untreated controls. However, similar basal NO levels
were observed between untreated controls, whole protocells, silica
cores and DOTAP:Chol lipid, suggesting that these materials do not gen-
erate transient or even subtle cell stress events.
4. Discussion
Our results demonstrate that mesoporous silica particle cores that
support either DOTAP:Chol or DOPC formulated liposomes (protocells)
release cargo (Dextran Rhodamine; a negatively charged ﬂuorophore)
when exposed to a range of pH values, with greater cargo release occur-
ring at pH 7.4 and higher. Interestingly, protocell cargo is optimally
retained at pH 6.0, while lower pH values again induce increased
cargo release. Both formulations resulted in high cellular-viabilityFig. 7. Intrathecal (i.t.; peri-spinal in direct meningeal contact) delivery of DOTAP:
Chol formulated protocells loaded with pDNA-IL-10 causes therapeutic reversal of
allodynia. (A and B) At pre-treatment baseline (BL) values, no signiﬁcant differences
were observed in threshold responses of either hindpaw (left and right; p > 0.05).
Following BL assessment, animals underwent a discrete CCI of the left sciatic nerve
to produce neuropathy, and threshold values were reassessed 3 and 10 days later
when robust allodynia was observed compared to sham-treated controls (ipsilateral
to CCI, F(8,36) = 4.94; p b 0.0004; contralateral to CCI, F(8,36) = 19.89; p b 0.0001).
On Day 10 after CCI, rats then received an i.t. injection of DOTAP:Chol protocells load-
ed with pDNA cargo (10 μg) encoding either IL-10 or non-encoding pDNA (as a gene
therapy control), or vehicle (20 μl isotonic saline). A signiﬁcant bilateral reversal of
allodynia reached signiﬁcance on Day 12 after CCI (Day 2 after i.t. injection) that re-
liably continued through Day 22, with partial reversal observed on Day 24 (ipsilateral
hindpaw: F(4,108) = 44.91; p b 0.0001, contralateral hindpaw: F(4,108) = 85.09;
p b 0.0001). Black squares represent CCI + i.t. pDNA-IL-10 (n = 7), black triangles
represent non-coding CCI + pDNA (n = 5), black circles represent CCI + saline
(n = 3), open triangles represent sham (no CCI) + i.t. non-coding pDNA (‘control
pDNA’, n = 5), and open circles represent sham + vehicle (n = 3). Black arrow in-
dicates i.t. injection, ‘Inj’; *p b 0.05; **p b 0.01; and ***p b 0.0001. (C) Nitric oxide
(NO) production was assessed to determine cell-stress responses following a 24 hr
incubation with DOTAP:Chol protocells loaded with pDNA-IL-10 cargo in the macro-
phage cell line, Raw 264.7 (n = 4–5 wells/condition). LPS, that classically induces
cell stress pathways and stimulates NO production (black bar), was used as a positive
control. NO levels in cell supernatant from cells without treatment (‘No Tx’, white
bar) to assess background levels of NO, DOTAP:Chol protocells (‘PC’, hatched bar),
or constituents of protocells such as the mesoporous silica core (‘Core’, 500 μg; hori-
zontal striped bar) or Dotap:Chol lipid (‘Lipid’, vertical striped bars) were assessed for
NO levels. While no signiﬁcant increase in NO production was observed in cell super-
natants following treatment with protocells or its constituents compared to the no
treatment controls, LPS treated cells revealed signiﬁcantly elevated NO levels com-
pared to core, lipid or PC treatment (F(4,14) = 321.8; p b 0.0001).
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Additionally, peri-spinal application (subarachnoid, intrathecal; i.t.) of
either DOTAP:Chol protocells or DOPC formulated protocells in separate
groups of rats resulted in minimal sensory changes. Subtle but signiﬁ-
cant differences in hindpaw sensory threshold values were generally
lower in DOPC protocell-treated rats at 2 h compared to thresholds of
DOTAP:Chol protocell treated rats (Fig. 3A–D). Importantly, assessment
for threshold changes in light mechanical touch from baseline is a sensi-
tive surrogate indicator for physiological spinal cord perturbations involv-
ing early-phase inﬂammatory processes [35] including the generation of
nitric oxide (NO) with consequent reactive oxygen species formation
and proinﬂammatory cytokine production (e.g. interlukin-1beta, IL-1β
and tumor necrosis factor-alpha, TNF-α) [19,21,36–39]. The damaging
effects of subtle inﬂammatory processes often go undetected when only
employing overt observations for general health measures such as
ambulatory function and body weight gain. In studies reported here, an
8-wk observation period for bodyweight gain revealed no differences be-
tween i.t. saline treated and DOTAP:Chol protocell and DOPC protocell-
treated animals (Fig. 3E). Spinal immunohistochemical examination of
DOTAP:Chol protocells containing DNA revealed clear co-localization
with macrophage/microglial cells at the spinal-meningeal interface
(Fig. 4D), with a complete lack of cell death, as indicated by the absence
of immunoreactivity for the late phase necessary apoptotic enzyme,
Caspase-3 (Fig. 4C). Cargo are co-localized with mesoporous silica-Nanoporous
Silica Core
Supported Lipid Bilayer
DOPC
or
DOTAP:Chol
Fig. 8. Schematic representation of the mesoporous silica particle-supported lipid bilaye
DNA-IL-10 gene (pDNA-IL-10) used in this report. The typical 2D hexagonal mesoporous sili
and at the surface of the protocell, while smaller diagnostic molecules (18-bp DNA and DexR
for DOTAP, cholesterol, DOPC and DexRho are provided.supported DOTAP:Chol liposomes observed 3 days following i.t.
protocell injection (Fig. 4H).
While these ﬁndings support that DOTAP:Chol protocells offer a
signiﬁcant degree of biocompatibility, clear differences were ob-
served in vivo between the biodistribution of DOTAP:Chol formulat-
ed and DOPC formulated protocells. Both DOTAP:Chol and DOPC
formulated protocell cargo surrounding the spinal cord injection
site were identiﬁed for as long as 8 weeks following administration
(Fig. 5B), but only DOPC protocells revealed an increased spread to
brain observed at 8 weeks (Fig. 5A and Table 2). Furthermore, IL-10
transgene expression in vitrowas signiﬁcantly greater following cel-
lular incubation with DOTAP:Chol-protocells containing plasmid
DNA encoding IL-10 (pDNA-IL-10) than cells incubated with DOPC
protocells containing pDNA-IL-10 cargo (Fig. 6A, B). Additionally,
DOTAP:Chol protocells revealed superior transfection efﬁciency to
naked pDNA-IL-10 or DOTAP:Chol liposomes alone (Fig. 6D).
Based on the overall proﬁle of DOTAP:Chol protocells as highly bio-
compatible, localized biodistribution and greater transgene expression,
DOTAP:Chol protocells loaded with pDNA-IL-10 cargo were examined
for their in vivo therapeutic potential as a novel non-viral gene transfer
vector delivered to the spinal cord to treat peripheral neuropathic pain.
Compared to various control-treated rats, i.t. injections of DOTAP:Chol
pDNA-IL-10 protocells resulted in robust reversal of allodynia for as
long as 12 days (Fig. 7A, B). Importantly, inﬂammatory nitric oxide,Supercoiled
Plasmid DNA-IL-10
18 bp-DNA 
Oligomer 
Labeled with 
6-carboxylfluouocein
Dextran tetramethylrhodamine
(DexRho)
r representing the theoretical loading of the diagnostic molecules and the plasmid
ca is depicted. Supercoiled pDNA-IL-10 (~50 nm) is primarily in between the liposome
ho) load into the silica pores as well as interact with the liposomes. Chemical structures
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ally absent in macrophages exposed to the composite DOTAP:Chol
protocell formulation or its constitutive components (Fig. 7C).
A schematic illustration of the mesoporous silica supported lipid
bilayer (protocells) showing the theoretical loading characteristics
of the diagnostic tools used in these studies (DexRho, 18-bp DNA)
or the therapeutic agent, pDNA-IL-10 is shown (Fig. 8). The 5.9 kb
pDNA-IL-10 is likely supercoiled and interacts both in between the
silica core and the lipid bilayer, but also at the surface of the positively
charged DOTAP:Chol lipid bilayer. In future studies, next-generation
mesoporous silica cores engineered with ultra large pores are predict-
ed to greatly improve the therapeutic gene delivery as other groups
have successfully demonstrated [40,41]. It is important to note that
the mesoporous silica cores used in these studies increase loading ca-
pacity of small molecules that serve a diagnostic function, or can en-
hance therapeutic efﬁcacy of drugs or transgene uptake.
The data provided in this report show that protocells are capable of
prolonged drug delivery, as DOTAP:Chol-protocells release ~35–40% of
negatively charged cargo at pH 7.4, which mimics CSF as well as extra-
cellular pH, during a 1 week timeframe. Protocells at pH 6.0 only re-
lease ~25–30% of cargo within a 72 h time frame, which although
speculative, may be exploitedwhen increased cargo retention is desired
during late endosomal trafﬁcking. Importantly, a substantial amount of
protocell cargo content remains for as long as 1 week, supporting the
possibility that enduring protocell cargo release for many weeks can
be achieved resulting in long-duration therapeutic transgene efﬁcacy.
This is particularly desirable for the treatment of chronic CNS diseases
such as chronic neuropathic pain. Future studies will determinewheth-
er trafﬁcking to late lysosomes containing ~3–4 pH values results in a
signiﬁcant amount of cargo release. While the mechanism of protocell
escape from lysosomes remains unknown, pH-dependent cargo release
may support an approach that optimizes cargo delivery to speciﬁc intra-
cellular compartments with low pH environments. Confocal microsco-
py shown in the current report demonstrates that protocell cargo is
indeed present within and adjacent to cellular nuclei of macrophages
in the spinal meninges surrounding the injection site. These observa-
tions suggest that while protocells do not necessarily need to enter
the nucleus for transgene host cell gene activation, nuclear localization
is possible.
While mesoporous silica particles have been widely studied and
characterized for in vitro biocompatibility, high cargo capacity, tun-
able pore diameters and surface chemistries [18,42–47], this report
is the ﬁrst in vivo demonstration of protocells as non-toxic and func-
tionally capable non-viral spinal gene therapy vectors. The therapeu-
tic application of protocells is highly beneﬁcial for several critical
reasons. First, factors indicative of cell stress (nitric oxide; NO) is ab-
sent following exposure to whole protocells or the components of
protocells (Fig. 7C). Inducible NO is a factor that is rapidly produced
following cell stress and inﬂammation known to mediate the induc-
tion of reactive oxygen species further contributing to cell stress
[48,49]. Proinﬂammatory IL-1β and TNF-α typically contribute to
additional NO production, creating ongoing inﬂammatory processes.
Second, the current data also reveal a lack of in vivo spinal perturba-
tions (e.g. inﬂammatory responses) following spinal protocell appli-
cation (Fig. 3A–D). Indeed, sensory hindpaw response-thresholds
remained unchanged from baseline, a physiological ‘read-out’ of
healthy conditions. Third, we further demonstrate that spinal tissue
immunohistochemical examination indicated the complete absence
of activated Caspase-3 (Fig. 4C), a critical enzyme that mediates
programmed cell death [50]. Additionally, we speculate that a large
percentage of i.t. protocells escape to the blood circulation where
they are cleared by the liver and kidneys with 24h, as protocells or
their cargo was absent from peripheral tissues examined at 72 h.
Close behavioral assessment, from minutes (30 min), to hours (1, 2,
3, 24 & 72), to weeks (up to 8 weeks) strongly supports a lack of
adverse reactivity (normal sensory proﬁles and weight gain).Collectively, these properties of protocells make them attractive plat-
forms for non-viral drug or gene delivery using a range of formula-
tions. In the current study, this ﬁrst-generation protocell supporting
a DOTAP:Chol lipid bilayer appears to be functionally effective as spi-
nal gene delivery vehicles for pain-related therapeutic purposes.
The majority of worldwide clinical trials using non-viral gene de-
livery techniques currently represents ~27% of the total gene therapy
clinical trials [51], with these trials mostly applying naked plasmid
DNA, and none aimed at neuropathic pain control. However, the ex-
amination of gene therapy applications for neuropathic pain in ani-
mal models has signiﬁcantly increased during the past dozen years,
with candidate gene products intended to disrupt pain-associated
biochemical changes, or themselves, act as analgesics [52]. These
trends point to the extraordinary need for new approaches toward
developing novel pain therapeutics, as currently available drugs are
minimally effective for pathological pain. Thus, the emerging area of
CNS gene therapeutics for pain control is rapidly growing.
Neuropathic pain results from pathology in the nervous system
and arises from aberrant signals in sensitized injured axons in the pe-
ripheral and/or central nervous system [53]. The anti-inﬂammatory
cytokine, IL-10, leads to exceptionally robust suppression of several
pain-related conditions including allodynia in various animal models
[54]. Allodynia, as assessed in this study, is a pathological sensory
condition whereby non-noxious stimuli such as mechanical light
touch to the skin are processed as painful [55], and spinal IL-10
gene therapy results in prolonged suppression of chronic allodynia
[56]. Indeed, non-viral naked plasmid DNA or polymer-encapsulated
gene therapy to control neuropathic pain has been successfully dem-
onstrated in animal models of neuropathic pain [12,13,23]. Interest-
ingly, these non-viral approaches are thought to harness phagocytic
innate immune cells that are present at low levels in the peri-spinal
meninges and subarachnoid space [12], as an increase in phagocytic
macrophages accumulate surrounding the intrathecal lumbar spinal
injection site. However, the transgene dose, release rate and cellular
targets are constrained by the method of gene delivery used in
these prior studies. Conversely, increased transgene dose (cargo re-
tention) and greater ﬂexibility in DNA release rate may be achieved
in future-generation protocells used as delivery platforms.
The prior established efﬁcacy of IL-10 for pain control allows com-
parisons with novel gene delivery approaches, like protocells, that re-
sult in therapeutic pain-suppression, and enables one to identify new
and improved gene and drug carrier platforms with promising clinical
applications. Our data demonstrate that this ﬁrst-generation DOTAP:
Chol protocell formulation is a highly feasible carrier platform for spi-
nal gene therapy. It is important to note that developing next-
generation protocell platforms are aimed at delivering cargo that act
to stimulate transgene uptake; a multi-therapy approach, and may
be superior to existing approaches.
5. Conclusions
This work characterizes the in vitro cell stress and in vivo physio-
logical proﬁle of liposomes fused on mesoporous silica particles, and
examines their use as gene therapeutic vectors delivered to the spinal
cord. These liposome-supported mesoporous silica particle constructs
are referred to as protocells, which act to retain and protect DNA
cargo used in these studies. The advantage of applying protocells as
cargo delivery systems (drug and genes) lies not only in their poten-
tial for exceptional cargo capacity, but also, as demonstrated in this
report, in their high and enduring biocompatibility within the CNS.
As non-viral vectors, protocells allow transgenes of interest to remain
physiologically functional. Most intriguing is the potential application
of this approach to other CNS diseases [57,58] where future-
generation protocells can be engineered for cell-speciﬁc targeting
and tunable release rates. The data in this report demonstrate
that protocells loaded with the IL-10 transgene and delivered
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ports that spinal IL-10 gene therapy leads to a reduction of pain
[12–14,16,23,59,60]. Thus, protocells offer a potentially new drug de-
livery vessel to the CNS with intrinsic ﬂexibility to tailor drug therapy.
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